Case Report

Mitochondrial Disorder Aggravated by Propranolol

Authors: Josef Finsterer, MD, PHD, Ellen Gelpi, MD

Abstract

Although there are indications that β-blockers affect the skeletal muscle in therapeutic dosages, their influence on mitochondrial disorders is unknown. A 52-year-old woman developed double vision, myalgias, muscle cramps, and hip and thigh muscle stiffness. Clinical neurologic examination revealed ptosis, dysarthria, sore neck muscles, weakness and wasting of the thighs, and generally brisk tendon reflexes. Lactate stress testing was significantly abnormal. Needle electromyography was nonspecifically abnormal and myopathic. Muscle biopsy showed mild myopathic changes, target fibers, and a single COX-negative fiber. Probable mitochondrial disorder was diagnosed. The patient had been on 30 mg of propranolol during 7 years for arterial hypertension. Shortly after discontinuation of the drug, her double vision gradually disappeared, myalgias and muscle cramps gradually resolved, and the patient reported an increase in muscle mass on repeated follow-ups. Long-term administration of propranolol may aggravate a mitochondrial disorder. Discontinuation of propranolol may result in a gradual resolution of these adverse reactions.


Key Points


* Propranolol may aggravate skeletal muscle manifestations in mitochondrial disorder.


* Discontinuation of propranolol gradually relieves adverse reactions in patients with mitochondrial disorder.


* β-blockers should be given with caution in mitochondrial disorder.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084–1089.
 
2. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052–1059.
 
3. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997;26 (Suppl 2):43–53.
 
4. Goli AK, Goli SA, Byrd RP Jr, et al. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002;72:461–464.
 
5. Lebrecht D, Setzer B, Ketelsen UP, et al. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation2003;108:2423–2429.
 
6. Norman C, Howell KA, Millar AH, et al. Salicylic acid is an uncoupler and inhibitor of mitochondrial electron transport. Plant Physiol 2004;134:492–501.
 
7. Felmus MT, Patten BM, Hart A, et al. Catecholamine-induced muscle weakness. Arch Neurol1977;34:280–284.
 
8. Forfar JC, Brown GJ, Cull RE. Proximal myopathy during beta-blockade. Br Med J 1979;2:1331–1332.
 
9. Imai Y, Watanabe N, Hashimoto J, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol 1995;48:29–34.
 
10. Kuncl RW, Meltzer HY. Beta adrenergic-mediated myofibrillar disruption and enzyme efflux in an experimental myopathy related to isometric muscle activity. Exp Mol Pathol 1979;31:113–123.
 
11. Blessing W, Walsh JC. Myotonia precipitated by propranolol therapy. Lancet 1977;1:73–74.
 
12. Nirmala G, Brahmayya Sastry P. Neuro-muscular depressant action of pindolol in comparison with propranolol and procaine. Arch Int Pharmacodyn Ther 1979;238:196–205.
 
13. Zaiton Z, Merican Z, Khalid BA, et al. The effects of propranolol on skeletal muscle contraction, lipid peroxidation products and antioxidant activity in experimental hyperthyroidism. Gen Pharmacol1993;24:195–199.
 
14. Jasek W. Austria-Codex. Fachinformation. Österreichische Apothekerverlagsgesellschaft, Wien, 2004.
 
15. Cocco T, Cutecchia G, Montedoro G, et al. The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase. J Bioenerg Biomembr 2002;34:251–258.
 
16. Almotrefi AA, Dzimiri N. Effects of beta-adrenoceptor blockers on mitochondrial ATPase activity in guinea pig heart preparations. Eur J Pharmacol 1992;215:231–236.
 
17. Wei YH, Lin TN, Hong CY, et al. Inhibition of the mitochondrial Mg2+-ATPase by propranolol.Biochem Pharmacol 1985;34:911–917.